Acumen Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Acumen Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($26.45M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($40.95M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($28.80M) | May 13, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($29.77M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($20.54M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($14.87M) | May 13, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($12.96M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($11.61M) | Aug 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($11.31M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($10.71M) | Nov 13, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($10.15M) | Aug 8, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($9.13M) | May 9, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($3.90M) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($61.36M) | Aug 15, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($27.00M) | May 16, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($2.49M) | Nov 15, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($2.04M) | Aug 16, 2021 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($26.51M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($41.75M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($30.37M) | May 13, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($32.27M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($24.38M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($17.77M) | May 13, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($16.04M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($13.48M) | Aug 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($13.14M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($11.37M) | Nov 13, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($10.41M) | Aug 8, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($9.21M) | May 9, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($3.94M) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($3.44M) | Aug 15, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($3.79M) | May 16, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($2.49M) | Nov 15, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($2.04M) | Aug 16, 2021 |